세계의 신속 진단 키트 시장 예측(2025-2030년)

The Global Rapid Diagnostic Kits Market is set to expand from USD 25.470 billion in 2025 to USD 36.083 billion by 2030, at a CAGR of 7.22%.

Rapid diagnostic kits deliver quick, preliminary medical results, enabling timely treatment with minimal resources. Designed for ease of use by individuals with limited medical expertise, these kits are vital for early disease detection. The market is driven by the rising prevalence of chronic diseases like cardiovascular diseases (CVD) and diabetes, coupled with growing awareness of early intervention. Technological advancements enhance kit accessibility and functionality, fostering market growth. However, limitations such as inaccurate results, the need for confirmatory microscopic tests, and high recurring costs of consumables like disposable strips restrain expansion.

Market Drivers

Rising Prevalence of Chronic Diseases

The increasing incidence of cardiovascular diseases and diabetes significantly propels the demand for rapid diagnostic kits, particularly cardiometabolic testing kits. CVD remains a leading global cause of mortality, with heart attacks and strokes often preventable through early detection. Diabetes, another major health concern, necessitates regular monitoring, boosting the demand for glucose monitoring kits. The surge in related conditions like hypertension and hyperlipidemia further drives the need for diagnostic tools to facilitate timely interventions, supporting market growth.

Growing Awareness and Accessibility

Increased awareness of preventive healthcare, especially in developed regions, encourages the adoption of rapid diagnostic kits. These kits cater to health-conscious consumers seeking convenient, fast solutions for monitoring conditions like blood glucose or drug use. The accessibility of kits for pregnancy and drug-of-abuse testing, offering quick results, also contributes to market expansion. However, the market faces challenges from competing diagnostic solutions, such as home testing and virtual reporting services, which limit the scope of rapid kits.

Market Restraints

The accuracy of rapid diagnostic kits is a significant limitation, as false-positive or false-negative results necessitate confirmatory microscopic tests, reducing their standalone reliability. High costs of consumables, such as glucose monitor strips, and battery limitations add to operational expenses, particularly in low- and middle-income regions where awareness and affordability are lower. Advancements in alternative diagnostic technologies further constrain market prospects by offering more precise or comprehensive solutions.

Market Segment Analysis

The market is segmented by application into glucose monitoring, cardiometabolic testing, infectious disease testing, drug-of-abuse testing, fertility and pregnancy testing, and others. Cardiometabolic testing kits are expected to grow significantly due to the rising prevalence of CVD and diabetes. Glucose monitors are critical for diabetes management, while drug-of-abuse and pregnancy testing kits gain traction due to their ease of use and rapid results. By distribution, the market includes various channels, with accessibility driving adoption across segments.

Geographical Outlook

North America is poised to dominate the rapid diagnostic kits market, driven by high disease prevalence, robust healthcare infrastructure, and widespread awareness campaigns. Organizations like the American Heart Association (AHA) and American Medical Association (AMA) promote preventive health measures, boosting kit adoption. The Asia-Pacific region, however, is projected to grow at the fastest rate, fueled by the rising burden of non-communicable diseases (NCDs) like CVD, diabetes, and cancer. Increasing government healthcare investments and growing awareness support market expansion, though high costs and lower adoption rates in some areas pose challenges.

The rapid diagnostic kits market is set for growth, driven by the rising incidence of chronic diseases and increasing demand for accessible, user-friendly diagnostic tools. Cardiometabolic and glucose monitoring kits lead due to their relevance in managing prevalent conditions. North America holds the largest market share, while Asia-Pacific promises rapid growth. Despite technological advancements, accuracy issues, high costs, and competition from alternative diagnostics limit potential. Industry stakeholders must focus on improving kit reliability and affordability to capitalize on global health trends.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Technology

• Lateral Flow Assay
• Agglutination
• Others

By Application

• Glucose Monitoring
• Cardiometabolic Testing
• Infectious Disease Testing
• Drugs-of-Abuse Testing
• Fertility & Pregnancy Testing
• Others

By End-User

• Hospitals & Clinics
• Diagnostics Centers
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Taiwan
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL RAPID DIAGNOSTIC KITS MARKET BY TECHNOLOGY

• 5.1. Introduction
• 5.2. Lateral Flow Assay
• 5.3. Agglutination
• 5.4. Others

6. GLOBAL RAPID DIAGNOSTIC KITS MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Glucose Monitoring
• 6.3. Cardiometabolic Testing
• 6.4. Infectious Disease Testing
• 6.5. Drugs-ON-Abuse Testing
• 6.6. Fertility & Pregnancy Testing
• 6.7. Others

7. GLOBAL RAPID DIAGNOSTIC KITS MARKET BY END-USER

• 7.1. Introduction
• 7.2. Hospitals & Clinics
• 7.3. Diagnostics Centers
• 7.4. Others

8. GLOBAL RAPID DIAGNOSTIC KITS MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Israel
  • 8.5.4. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Taiwan
  • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Creative Diagnostics
• 10.2. Abbott Laboratories
• 10.3. NanoRepro AG
• 10.4. Atlas Medical UK
• 10.5. Coris BioConcept
• 10.6. Roche Diagnostics
• 10.7. SD Biosensor
• 10.8. ACON Laboratories Inc.
• 10.9. Alfa Scientific Designs Inc.
• 10.10. AdvaCare Pharma

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key benefits for the stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations